NorthSea Therapeutics Announces Positive Phase 2b Trial Results

NorthSea Therapeutics B.V., a private biotech company focused on treating metabolic, cholestatic, and fibrotic diseases, has announced successful results from its Phase 2b ICONA clinical trial, examining the effects of its compound, icosabutate, on F1-F3 metabolic dysfunction-associated steatohepatitis (MASH). Published in the Journal of Hepatology, the trial highlights icosabutate's unique anti-fibrotic mechanism that works independently of liver fat reduction. The trial results, assessed via AI-assisted and conventional histology, demonstrate significant improvements in fibrosis and various biomarkers of liver health. The study supports the potential of icosabutate for combination therapies, especially in MASH patients, by targeting factors like glycemic control and inflammation.